Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Should Value Investors Pick BioDelivery (BDSI) Stock Now?

Let's see if BioDelivery (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

Why Is BioDelivery (BDSI) Down 20.8% Since Last Earnings Report?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Analysts Estimate BioDelivery Sciences International (BDSI) to Report a Decline in Earnings: What to Look Out for

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BioDelivery (BDSI) Up 3.2% Since Last Earnings Report: Can It Continue?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery Sciences International (BDSI) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BioDelivery Sciences International (BDSI) Beats Q2 Earnings Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of 80.00% and -1.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery Sciences International (BDSI) Misses Q1 Earnings Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Down 12.8% Since Last Earnings Report: Can It Rebound?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moving Average Crossover Alert: BioDelivery Sciences (BDSI)

BioDelivery Sciences (BDSI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

BioDelivery (BDSI) Beats Q4 Earnings Estimates, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. The company expects total revenues to be in the range of $170 - $180 million in 2021.

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Up 9.5% Since Last Earnings Report: Can It Continue?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is a BioDelivery Sciences (BDSI) Good Value Investor Stock?

Let's see if BioDelivery Sciences International (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Down 15.5% Since Last Earnings Report: Can It Rebound?

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.

BioDelivery Sciences International (BDSI) Q2 Earnings Lag Estimates

BioDelivery (BDSI) delivered earnings and revenue surprises of -75.00% and 0.87%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: BioDelivery Sciences International (BDSI) Q2 Earnings Expected to Decline

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

What Bargain Hunting? Tap 5 Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.